



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/852,965	05/10/2001	Scott F. Sneddon	2478.1002-002	4903

30093 7590 12/12/2001

GENZYME CORPORATION C/O HAMILTON, BROOK, SMITH
& REYNOLDS
HAMILTON, BROOK, SMITH & REYNOLDS, PC
TWO MILITIA DRIVE
LEXINGTON, MA 02421-4799

EXAMINER

BALASUBRAMANIAN, VENKATARAMAN

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 12/12/2001

5

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/852,965	Applicant(s) SNEDDON ET AL.
Examiner Venkataraman Balasubramanian	Art Unit 1624



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on _____

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-107 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims 1-107 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____

16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other: _____

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4,7-14, 33-48, 51-70 and 102, drawn to compound of formula I or II wherein W and Z both are nitrogens, namely triazine, and method of use, classified in class 544, subclasses 207, 212, class 514, subclass 241.
- II. Claims 1-6, 33-50 and 101-107, drawn to compound of formula I and others wherein one of W and Z is nitrogen, the other carbon, namely pyrimidine, classified in class 544, subclasses 324 and 328, class 514, subclasses 256 and 272.
- III. Claims 1-4 and 33-48, drawn to compound of formula I wherein W, Z are carbons and V is nitrogen, classified in class 544, subclass 405, class 514, subclass 255.05.
- IV. Claims 1-4 and 33-48, drawn to compound of formula I wherein W, Z and V are carbons namely pyridine and method of use, classified in class 546, subclass 282.1, class 514 subclass 340.
- V. Claims 15-32 and 71-100, drawn to diamide compound shown in claim 15, composition and method of use classified in classes various, subclass various depending upon the choice of substituents including subclasses of class 564.

The inventions are distinct, each from the other because of the following reasons:

Group I-V are independent and distinct from each other because they are directed to structurally dissimilar compounds that lack common core such as triazine vs pyrimidine vs piperazine vs pyridine vs diamide core. Consequently, the groups have different classifications and require separate prior art searches. They can be made and used independently. Art, which may render obvious or anticipate one of the groups, would not necessarily do the same for the other group as evidenced by the references cited in the Information Disclosure Statement provided by the applicants. Each can support a patent, as the compounds of each group are capable of being utilized alone not in combination with other members listed in the Markush group. Placing all such compounds into the same claims is proper to scientific classification as they are separately classified and require separate searches.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

In view of distinct nature of each of the inventions, the restriction is set forth in writing.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication from the examiner should be addressed to Venkataraman Balasubramanian (Bala) whose telephone number is (703) 305-1674. The examiner can normally be reached on Monday through Thursday from 8.00 AM to 5.30 PM.

The fax phone number for the organization where this application or proceeding is assigned (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

V. Balasubramanian
Venkataraman Balasubramanian (Bala)

12/8/2001